The trial laid the foundation for the Comparative Immunotherapy Program — a program launched a year ago to tap into Penn’s ...
Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment: Indianapolis Monday, October 20, 2025, 12:00 Hrs [IST] Eli Lilly and ...
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback